Compulsory Licensing: How Governments Override Patents for Public Health

When a life-saving drug costs too much, who gets to decide if it should be made cheaper? That’s where compulsory licensing comes in. It’s not a secret loophole or a radical policy-it’s a legal tool written into international trade law that lets governments step in and authorize generic manufacturers to produce patented medicines without the drug company’s permission. The catch? The company still gets paid. But not at the price they want. At a price that keeps people alive.

This isn’t theoretical. In 2012, India issued a compulsory license for Nexavar, a kidney and liver cancer drug made by Bayer. The original price? Around $5,500 per month. After the license, a local company started making it for under $200. That’s a 96% drop. People who couldn’t afford treatment suddenly could. And it didn’t break the patent system-it forced it to serve real people, not just profits.

How Compulsory Licensing Works

At its core, compulsory licensing is about balance. Patent law gives companies exclusive rights to make and sell their inventions-for up to 20 years. That’s meant to reward innovation. But what if that innovation is locked away because the price is too high? That’s when governments can step in.

The legal foundation comes from the TRIPS Agreement a 1994 global treaty under the World Trade Organization that sets minimum standards for intellectual property rights, including rules for compulsory licensing. Article 31 says governments can issue these licenses under specific conditions: the patent holder must be paid fairly, the license is usually only for the domestic market, and the government must try to negotiate first. But here’s the key exception: if there’s a national emergency or extreme urgency, like a pandemic, the negotiation step can be skipped.

Think of it like this: if your house is on fire, you don’t wait for the neighbor’s permission to use their hose. You grab it. Compulsory licensing is the legal version of that.

Where It’s Used-And Where It’s Not

Not every country uses this tool. Some barely even try.

In the United States a country with one of the most restrictive compulsory licensing frameworks, where only 10 licenses have been issued since 1945, the government mostly uses it for its own military or federal agencies under 28 U.S.C. § 1498 a law allowing federal use of patented inventions with compensation. The Bayh-Dole Act a 1980 law that lets the government "march in" and force licensing of federally funded research was supposed to ensure taxpayer-funded science benefits the public. But since 1980, the National Institutes of Health has received 12 petitions to use this power-and denied every single one.

Meanwhile, India a country that has issued 22 compulsory licenses between 2005 and 2021, mostly for cancer drugs has become the global leader in using this tool. Brazil, Thailand, and South Africa have all used it for HIV drugs. Thailand slashed the price of lopinavir/ritonavir from $1,200 a year to $230. Brazil cut efavirenz from $1.55 per tablet to $0.48. These aren’t small savings. These are life-or-death differences.

Europe is mixed. Germany has the legal right but has never issued one. Spain, during the pandemic, passed emergency rules that let it skip negotiation entirely. The EU as a whole is now pushing to make the process faster, with a 2023 proposal requiring drug companies to respond to licensing requests within 30 days-or risk automatic government authorization.

Why Drug Companies Fight It

It’s no surprise that pharmaceutical companies hate compulsory licensing. When a license is issued, their stock often drops. A 2022 study by the International Federation of Pharmaceutical Manufacturers & Associations found that each public announcement of a compulsory license caused an average 8.2% decline in company stock prices.

They argue it kills innovation. A 2018 study in the Journal of Health Economics suggested countries with active compulsory licensing saw 15-20% less R&D investment. But that’s only part of the story. The same study didn’t account for the fact that most of these countries are low- and middle-income nations that never had the money to buy the drugs in the first place. The real impact? When prices drop, more people get treated. That creates new markets. Teva Pharmaceutical made $3.2 billion between 2015 and 2020 from generic drugs produced under compulsory licenses.

And here’s the irony: the threat of compulsory licensing often works better than the license itself. Dr. Brook Baker, a law professor and public health advocate, found that the mere possibility of a government stepping in led to voluntary price cuts for 90% of HIV drugs in developing countries since 2000. Companies lowered prices just to avoid the public backlash.

The Real Barriers

It’s not just about the law. It’s about who can use it.

Only 12 countries have ever issued a compulsory license for pharmaceuticals. Why? Because the process is slow, expensive, and complex. In the U.S., filing under Section 1498 means suing the government in federal court. The average case takes 2.7 years. In India, applicants must prove they tried to negotiate, that the drug is needed for public health, and that they have the capacity to make it. The Intellectual Property Appellate Board takes 18 to 24 months to decide.

And then there’s the knowledge gap. The World Health Organization found that 60% of low- and middle-income countries don’t have the legal or technical expertise to even start the process. They know the law exists. But they don’t know how to use it.

That’s changing. The 2022 WTO agreement on COVID-19 vaccine patents was historic. For the first time, countries without manufacturing capacity could import generic vaccines made under compulsory license. Only 12 facilities in 8 countries have used it so far-but it set a precedent. And now, the WHO is drafting a Pandemic Treaty that would automatically trigger compulsory licensing during declared global health emergencies.

Who Benefits?

Not the patent holders. Not always the generic manufacturers. But the patients.

Between 2000 and 2020, compulsory licensing helped cut the price of first-line HIV medications by 92% in developing countries. That’s millions of people on life-saving treatment who otherwise wouldn’t have been.

It’s not about taking away patents. It’s about making sure they don’t become barriers to survival. A patent is meant to encourage innovation-not to hold patients hostage. Compulsory licensing doesn’t destroy the system. It fixes it when it fails.

What’s Next?

As antimicrobial resistance grows and climate-related health threats increase, governments will need more tools like this. The Boston Consulting Group predicts a 40% rise in compulsory licensing between 2023 and 2028.

The next frontier? Not just medicines. Think solar energy tech for rural clinics, water purification systems for drought zones, or diagnostic tools for remote areas. The same legal logic applies: when a patented invention is critical to public survival, the public interest must come first.

The debate won’t end. But the evidence is clear: when used wisely, compulsory licensing saves lives. And sometimes, that’s the only metric that matters.